Emyria’s MDMA Therapy Shows Lasting PTSD Relief in Early Clinical Data

• Average PTSD symptom scores dropped by 29.6 points at 3-month follow-up
• Quality of life improved significantly with a 23.5-point increase in ReQoL scores
• 100% treatment completion rate among initial eight patients with severe PTSD
• Mild and manageable side effects reported in one-quarter of patients